Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute Study

Jean R. Clemenceau, Sung Hak Lee, Peter Bazeley, Alex Millinovich, Jian Jin, Nathan Pennell, Davendra Sohal, Tae Hyun Hwang
doi: https://doi.org/10.1101/19013433
Jean R. Clemenceau
1Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sung Hak Lee
1Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Bazeley
1Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Millinovich
1Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Jin
1Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan Pennell
2Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Davendra Sohal
2Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tae Hyun Hwang
1Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hwangt{at}ccf.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Data Availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Back to top
PreviousNext
Posted December 04, 2019.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute Study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute Study
Jean R. Clemenceau, Sung Hak Lee, Peter Bazeley, Alex Millinovich, Jian Jin, Nathan Pennell, Davendra Sohal, Tae Hyun Hwang
medRxiv 19013433; doi: https://doi.org/10.1101/19013433
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Evaluation of Prognostic Utility of Tumor Mutation Burden for NSCLC response to Immune Checkpoint Blockade Therapy: A Single Institute Study
Jean R. Clemenceau, Sung Hak Lee, Peter Bazeley, Alex Millinovich, Jian Jin, Nathan Pennell, Davendra Sohal, Tae Hyun Hwang
medRxiv 19013433; doi: https://doi.org/10.1101/19013433

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)